At a glance Retatrutide is an investigational weekly injection from Eli Lilly, not yet licensed in the UK It targets three hormone receptors at once GLP-1, GIP and glucagon earning it the nickname "triple G" It reduces appetite, improves blood sugar, and appears to nudge resting energy expenditure upwards Phase 2 trial participants lost an average of around 24% of body weight over 48 weeks at the top dose Side effects mirror existing GLP-1 medications: nausea, mild gut symptoms, reduced appetite Expected UK approval is 18-24 months away pending Phase 3 results and MHRA review The basics: what retatrutide is Retatrutide is an investigational weekly injection being developed by Eli Lilly for weight loss and related metabolic conditions
The pharmacies in the Facility Inspections Warning Letters section are FDA-registered 503B outsourcing facilities. They operate under stricter oversight, must follow current good manufacturing process (cGMP), and use ingredients sourced from FDA-registered suppliers
It involves millions of sperm, specific timing, and optimal conditions for everything to align perfectly [1]
Theyre not a replacement for lifestyle modification
Effect of the Glucagon-Like Peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER
